Tags

Type your tag names separated by a space and hit enter

iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study.
Diabetes Obes Metab. 2020 May 03 [Online ahead of print]DO

Abstract

Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan-L study, we determined whether iGlarLixi, a fixed-ratio combination of insulin glargine Gla-100 (iGlar) and the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi), addresses the challenge of reducing residual hyperglycaemia in patients with T2D. In LixiLan-L, a randomized, open-label study, 1018 patients with T2D on basal insulin for ≥6 months ± oral antidiabetes drugs entered a 6-week run-in period, during which they were switched to and/or optimized for a daily dose of iGlar while continuing only metformin. Following the run-in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin. Residual hyperglycaemia was defined as HbA1c ≥ 7.0% despite FPG of <140 mg/dL. The proportion of patients with residual hyperglycaemia was similar in both treatment arms at screening (~~42%), and increased after the run-in period (~~62%). After 30 weeks, the proportion of patients with residual hyperglycaemia declined to 23.8% in the iGlarLixi versus 47.1% in the iGlar arm (P < .0001). The proportion of patients achieving both HbA1c (<7.0%) and FPG (<140 mg/dL) targets was higher in the iGlarLixi compared with the iGlar arm (50.3% vs. 27.4%, respectively; P < .0001). iGlarLixi effectively reduces residual hyperglycaemia in patients with T2D on basal insulin therapy.

Authors+Show Affiliations

University of Bari Aldo Moro, Bari, Italy.Mount Sinai Hospital, Toronto, Ontario, Canada.Hospital Clinic of Barcelona, Barcelona, Spain.Brigham and Women's Hospital, Boston, Massachusetts, USA.BDM Consulting, Somerset, New Jersey, USA.Sanofi, Bridgewater, New Jersey, USA.University of Bari Aldo Moro, Bari, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32363634

Citation

Morea, Nicola, et al. "IGlarLixi Effectively Reduces Residual Hyperglycaemia in Patients With Type 2 Diabetes On Basal Insulin: a Post Hoc Analysis From the LixiLan-L Study." Diabetes, Obesity & Metabolism, 2020.
Morea N, Retnakaran R, Vidal J, et al. IGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study. Diabetes Obes Metab. 2020.
Morea, N., Retnakaran, R., Vidal, J., Aroda, V. R., Liu, M., Saremi, A., & Giorgino, F. (2020). IGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study. Diabetes, Obesity & Metabolism. https://doi.org/10.1111/dom.14077
Morea N, et al. IGlarLixi Effectively Reduces Residual Hyperglycaemia in Patients With Type 2 Diabetes On Basal Insulin: a Post Hoc Analysis From the LixiLan-L Study. Diabetes Obes Metab. 2020 May 3; PubMed PMID: 32363634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - iGlarLixi effectively reduces residual hyperglycaemia in patients with type 2 diabetes on basal insulin: A post hoc analysis from the LixiLan-L study. AU - Morea,Nicola, AU - Retnakaran,Ravi, AU - Vidal,Josep, AU - Aroda,Vanita R, AU - Liu,Minzhi, AU - Saremi,Aramesh, AU - Giorgino,Francesco, Y1 - 2020/05/03/ PY - 2020/02/29/received PY - 2020/04/18/revised PY - 2020/04/29/accepted PY - 2020/5/5/pubmed PY - 2020/5/5/medline PY - 2020/5/5/entrez KW - GLP-1 analogue KW - basal insulin KW - phase III study KW - type 2 diabetes JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab N2 - Globally, nearly half of patients with type 2 diabetes (T2D) do not successfully achieve target HbA1c with basal insulin, despite meeting fasting plasma glucose (FPG) targets. In this post hoc analysis of the LixiLan-L study, we determined whether iGlarLixi, a fixed-ratio combination of insulin glargine Gla-100 (iGlar) and the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi), addresses the challenge of reducing residual hyperglycaemia in patients with T2D. In LixiLan-L, a randomized, open-label study, 1018 patients with T2D on basal insulin for ≥6 months ± oral antidiabetes drugs entered a 6-week run-in period, during which they were switched to and/or optimized for a daily dose of iGlar while continuing only metformin. Following the run-in period, 736 patients were then randomized to receive iGlarLixi or were continued on iGlar for 30 weeks ± metformin. Residual hyperglycaemia was defined as HbA1c ≥ 7.0% despite FPG of <140 mg/dL. The proportion of patients with residual hyperglycaemia was similar in both treatment arms at screening (~~42%), and increased after the run-in period (~~62%). After 30 weeks, the proportion of patients with residual hyperglycaemia declined to 23.8% in the iGlarLixi versus 47.1% in the iGlar arm (P < .0001). The proportion of patients achieving both HbA1c (<7.0%) and FPG (<140 mg/dL) targets was higher in the iGlarLixi compared with the iGlar arm (50.3% vs. 27.4%, respectively; P < .0001). iGlarLixi effectively reduces residual hyperglycaemia in patients with T2D on basal insulin therapy. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/32363634/iGlarLixi_effectively_reduces_residual_hyperglycaemia_in_patients_with_type_2_diabetes_on_basal_insulin:_A_post_hoc_analysis_from_the_LixiLan-L_study L2 - https://doi.org/10.1111/dom.14077 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.